SOURCE: StockCall


December 29, 2010 08:20 ET

Analyst Research on Mylan Inc. and Watson Pharmaceuticals Inc. -- Patent Cliffs and Lawsuits Rule the Generic Industry

JOHANNESBURG, SOUTH AFRICA--(Marketwire - December 29, 2010) - offers investors comprehensive research on the drugs - generic industry and has completed analytical research on Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Register with us today at to have free access to these researches. 

Generic drug makers which include the like of Mylan Inc. and Watson Pharmaceuticals Inc. have been on a bumpy ride lately. With the recent and coming expiry of many lucrative brand name drug patents, generic makers have been able to produce lower cost versions of popular medicine. With products such as the cancer drug Gemzar or the bad cholesterol fighting Lipitor now or soon to be available in generic versions, companies in the industry look well positioned moving forward. Investors looking for complimentary research on Watson Pharmaceuticals Inc. are welcome to sign up at for our new report. is an online platform where investors doing their due-diligence on the drugs - generic industry can have easy and free access to our analyst research and opinions on Mylan Inc. and Watson Pharmaceuticals Inc.; all investors need to do is register for a complimentary membership at

However, the industry has been facing its own set of challenges. A recent rash of government lawsuits over the alleged inflation of prescription prices has landed some generic companies such as Mylan Inc. in trouble. Some individual companies have had to pay settlements in the hundreds of millions of dollars while the figures for the industry are in the billions. Investors looking for free research on Mylan Inc. are welcome to sign up at for our new report. 

While the industry is rife with lawsuits such as the one Watson Pharmaceuticals Inc. is facing from Covidien Plc, some have been focusing their attention elsewhere. Product development, including receiving the all important FDA seal of approval, is being heavily invested in. Strategic partnerships in emerging markets have also been popular lately, as companies try to grab a larger market share. Register now at to have free access to our reports on the drugs - generic industry.

Visit to see how companies in this industry have grown over the past years and how they are expected to perform in the future.

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information